Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers
Izmirly P, Kim M, Friedman DM, Costedoat-Chalumeau N, Clancy R, Copel JA, Phoon CKL, Cuneo BF, Cohen RE, Robins K, Masson M, Wainwright BJ, Zahr N, Saxena A, Buyon JP. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. Journal Of The American College Of Cardiology 2020, 76: 292-302. PMID: 32674792, PMCID: PMC7394202, DOI: 10.1016/j.jacc.2020.05.045.Peer-Reviewed Original ResearchConceptsCongenital heart blockPrimary outcomeSecondary outcomesEndocardial fibroelastosisHeart blockRecurrence of CHBSSA/Ro-positive mothersAnti-SSA/RoMacrophage Toll-like receptorToll-like receptor antagonistsCutaneous neonatal lupusRo-positive mothersGestational weeks 10Toll-like receptorsFetal cardiac diseaseNeonatal lupusPositive mothersSecondary preventionSkin rashPrevious pregnancyTreat analysisClinical evidenceRecurrence rateReceptor antagonistOptimal approach